IMDELLTRA
RegisteredWord Mark
•
Ownership
AI
Owner Name
Type: Organization / Corporation
Address
One Amgen Center Drive
Thousand Oaks, CA 913201799
Critical Dates
First Use Date
May 21, 2024
Filing Date
Jul 29, 2022
Registration Date
Oct 1, 2024
Mark Descriptions
Goods
Class 5
pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations used for the treatment of lung, prostate and respiratory disorders
Mark Elements
Text Mark
IMDELLTRA
Category
Trademark
Standard Characters
Yes
Color Claim
No
Data source: USPTO TSDR
View on USPTO websiteTrademark Timeline
First Use
Filing Date
Publication Date
Registration Date
USPTO Records
| Title | Date | Category | Source | Pages | Format | Actions |
|---|---|---|---|---|---|---|
AI AssessmentCached Mar 12, 2026, 08:01 AMCached
AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.
Trademark Summary
The standard character mark IMDELLTRA covers pharmaceutical preparations used for the treatment of cancer and lung, prostate, and respiratory disorders in International Class 005. It is registered on the Principal Register (Reg. No. 7524164) with a registration date of October 1, 2024. Amgen Inc., a Delaware corporation based in Thousand Oaks, California, is the owner.
Recent Activity
Filed on July 29, 2022, the mark was published for opposition on May 16, 2023, followed by a Notice of Allowance on July 11, 2023. A Statement of Use was filed on May 23, 2024, accepted on August 27, 2024, leading to registration on October 1, 2024; attorney and correspondence changes occurred on February 25, 2025.
USPTO
AI Analysis
v2.8.0
Never miss important updates for this trademark
Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach